This research uses a high-throughput screening platform called EpiScan to identify HIV peptides that bind strongly to MHC molecules and appear on infected cell surfaces. By discovering these immune-visible targets, the work aims to improve detection and elimination of hidden HIV reservoirs, supporting the development of future HIV therapies.

This research investigates how cells select which protein fragments, or peptides, to display to the immune system. Contrary to previous assumptions, peptide presentation appears highly curated rather than random. Understanding these selection rules could improve cancer immunotherapy, enhance antiviral treatments, and provide new insights into autoimmune diseases.